Interim 12-month clinical trial results presented at the 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), in May, demonstrated the clinical efficacy of Ellex 2RT in partially halting or reversing the degenerative processes which cause AMD.
According to Tom Spurling, Ellex CEO, the results mean “for the first time, AMD can be treated before vision is lost.”
The trial, conducted in collaboration with Centre for Eye Research Australia (CERA) at the Royal Victorian Eye and Ear Hospital found that at 12 months, two-thirds of the 24 enrolled patients experienced an improvement in visual function and drusen reduction in the treated eye. The majority also noted an improvement in the fellow, untreated eye. Visual function improved predominately in the regions of greatest dysfunction, which are associated with the highest likelihood of progressing to the advanced stage of the disease. Extensive laboratory research to date shows no evidence of laser damage to photoreceptor cells.
“This is an extremely positive result. To date there has been no proven intervention in Early AMD that significantly halts or causes regression of the disease process,” commented Professor Robyn Guymer, MB, BS, PhD, FRANZCO, Head of Macular Research at the CERA.
“Our research shows that application of 2RT treatment is safe and painless, and results in both improved visual function and drusen resolution.”
